IGC Pharma, Inc. (NYSEAMERICAN:IGC – Get Free Report) was up 3.3% during trading on Tuesday. The company traded as high as $0.2848 and last traded at $0.2830. 604,284 shares changed hands during mid-day trading, a decline of 12% from the average session volume of 686,994 shares. The stock had previously closed at $0.2740.
Analyst Ratings Changes
IGC has been the subject of a number of research reports. Ascendiant Capital Markets lifted their target price on shares of IGC Pharma from $5.25 to $5.50 and gave the stock a “buy” rating in a research report on Monday, June 8th. Zacks Research upgraded shares of IGC Pharma to a “hold” rating in a research report on Friday, August 28th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, IGC Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.
Check Out Our Latest Stock Report on IGC
IGC Pharma Stock Performance
IGC Pharma (NYSEAMERICAN:IGC – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.03) EPS for the quarter. The company had revenue of $0.27 million during the quarter. As a group, analysts forecast that IGC Pharma, Inc. will post -0.1 EPS for the current fiscal year.
About IGC Pharma
IGC Pharma, Inc is a life sciences company focused on developing and commercializing cannabinoid-based therapies and other plant-derived pharmaceutical products. Its research and development efforts have included treatments for neurological and neurodegenerative conditions, including Alzheimer’s disease, as well as products intended to address pain, seizures and other health-related needs.
The company has developed proprietary cannabinoid formulations and has pursued clinical development and regulatory advancement for its lead therapeutic candidates.
Further Reading
- Five stocks we like better than IGC Pharma
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
